

Effects of Dapagliflozin against Cyclophosphamide-induced Hepatotoxicity in Male Rats in Comparison to Silymarin

By: Afrah Thiab

This presentation explores the mechanisms of cyclophosphamide-induced liver toxicity and investigates the potential of dapagliflozin and milk thistle as protective agents.



Cyclophosphamide: A Powerful Drug with Limitations


Cyclophosphamide (CPA)

A widely used drug for cancer and autoimmune diseases.

Challenge

Therapeutic doses cause liver toxicity, limiting its clinical use.

Mechanisms of CPA-Induced Hepatotoxicity



Oxidative Stress

Imbalance in oxidant/antioxidant systems.

Inflammatory Pathways

Lipid peroxidation activates signaling pathways.


Mitochondrial Damage

Impairs cellular respiration and disrupts balance.




Apoptosis

Reactive Oxygen Species induce apoptosis.

Cyclophosphamide




hepatic CYPs




4-Hydroxycyclophosphamide

enzymatic



4-Ketocyclophosphamide


aldehyde dehydrogenase




Carboxyphosphamide

Aldophosphamide

nonenzymatic



Phosphoramidate mustard



Acrolein

INACTIVE METABOLITES

TOXIC METABOLITES



Parameters of CPA-Induced Liver Toxicity

1

Biochemical Indicators

Increased hepatic enzyme activity: AST, LDH, ALP.

2

Inflammatory Markers

TNF- α , IL-1 β , anti-inflammatory marker IL-10.

3

Molecular Indicators

Apoptotic markers: Caspase-3, Bcl-2, HNF4 α .

Dapagliflozin: A Potential Hepatoprotective Agent

Overview

SGLT2 inhibitor approved for type 2 diabetes management.

Hepatoprotective Effects

Attenuates hepatic steatosis and reduces glucose uptake.

Milk Thistle: (Silymarin)

A Natural Hepatoprotective Agent



Anti-oxidative



Anti-inflammatory



Regenerative



Study Objectives

1

Understand CPA-Induced Liver Toxicity

Molecular mechanisms, biochemical, molecular, and histological parameters.

2

Evaluate Protective Effects of Dapagliflozin

Assess parameters like MDA, GSH, SOD, inflammatory markers, and apoptotic markers.



Methodology

1

Animal Model

Rats treated with CPA (30 mg/kg/day for 10 days).

2

Experimental Groups

Control, CPA-only, CPA + dapagliflozin and CPA + Silymarin

3

Analytical Techniques

Biochemical assays, qRT-PCR, Western blot, ELISA and histological analysis.

Key Findings (Expected Results)



Conclusion and Future Directions

1

CPA-induced hepatotoxicity

Mediated through oxidative stress, inflammation, and apoptosis.

2

Dapagliflozin

Shows promise as a protective agent.

3


Future Directions

Explore combined effects, investigate long-term outcomes, study molecular pathways.

Thank you listening!

Hepatoprotective

LIVER



LIVER

Thank you listening!

18283



10000 90000



Stomach & liver



100 200 300 400